On this Page
THE RISE OF DIY CLINICAL DATA SYSTEMS
WHY MANY STUDIES BEGIN WITH DIY SYSTEMS
Instead, these decisions are usually driven by practical constraints common in earlystage research organizations.
LIMITED BUDGETS
Early-stage companies often prioritize scientific development over infrastructure investment
SMALL CLINICAL TEAMS
Many startups launch studies with minimal clinical operations staff.
INTERNAL DEVELOPMENT OPTIMISM
Engineering teams may believe internal systems can be built quickly and inexpensively.
LACK OF REGULATORY FAMILIARITY
Executives outside clinical operations may not fully understand regulatory requirements for clinical data systems.
Because of these factors, many studies begin using combinations of general software tools.
Trial Function
Common DIY Tool
Patient surveys
REGULATORY RISK: THE HIDDEN COST OF DIY CLINICAL DATA SYSTEMS
Clinical trials that support regulatory submissions must follow strict requirements
governing data integrity, traceability, and system validation. These standards are
enforced by regulatory authorities worldwide, including:
- U.S. Food and Drug Administration (FDA)
- Health Canada
- European Medicines Agency (EMA)
- PMDA (Japan)
- MHRA (United Kingdom)
21 CFR PART 11 COMPLIANCE RISKS
- Secure user authentication
- Controlled access to records
- Electronic signatures
- Protection against unauthorized data changes
- Complete audit trails
- Validated system performance
Trial Function
Common DIY Tool
DATA PRIVACY RISKS (GDPR AND HIPAA)
Clinical trials frequently involve sensitive personal information, including:
- Protected Health Information (PHI)
- Personally Identifiable Information (PII)
- Improvised systems may fail to meet requirements under:
- HIPAA (United States) for PHI protection
- GDPR (European Union) for personal data privacy
- national data protection laws in many jurisdictions
- Improper handling of clinical data can lead to:
- Regulatory investigations
- Financial penalties
- Mandatory breach notifications
- Reputational damage
REAL-WORLD CONSEQUENCE: STUDY DATA REJECTION
In some cases, sponsors discover these compliance gaps only after significant data has been
already been collected.
When regulators determine that electronic records cannot be trusted due to missing
audit trails or system validation, the data may be considered unreliable for regulatory
submission.
- Repeat data collection
- Reconstruct missing audit trails
- Migrate data into validated systems
- Conduct additional monitoring and verification
- In extreme cases, entire studies may need to be repeated.
The financial impact of repeating a clinical study can exceed millions of dollars, far
surpassing the cost of implementing validated systems at the beginning of the trial.
WHY VALIDATED SYSTEMS EXIST
- Immutable audit trails
- Electronic signatures compliant with 21 CFR Part 11
- Controlled user access and permissions
- System validation documentation
- Secure data storage and encryption
DATA INTEGRITY CHALLENGES
DATA QUALITY AND DATA INTEGRITY RISKS
- Inconsistent data formatting
- Manual transcription errors
- Missing fields or incomplete records
- Difficulty tracking changes to data
Modern electronic data capture systems address these challenges through
structured data entry and configurable validation rules.